AbbVie coughs up nearly $50M for Cugene’s autoimmune med in a bid to shore up life post-Humiranews2022-05-16T13:39:55+00:00May 16th, 2022|FierceBiotech|
To TIGIT or not to TIGIT? Roche’s latest trial flop casts shadow on Big Pharma’s $6B betnews2022-05-16T11:40:52+00:00May 16th, 2022|FierceBiotech|
From Redditors to creditors: Orphazyme’s wild ride ends with $13M sale to satisfy bankruptcy courtnews2022-05-16T10:07:21+00:00May 16th, 2022|FierceBiotech|
Shionogi splashes $100M on F2G’s rare fungal disease drug to unlock new class of medicinenews2022-05-16T09:30:07+00:00May 16th, 2022|FierceBiotech|
Kriya cashes in $270M series C to further finance all-in-one gene therapy biznews2022-05-15T22:02:47+00:00May 15th, 2022|FierceBiotech|
mRNA Unlocked: How Technology Convergence Is Driving the Next Wavenews2022-05-13T16:39:15+00:00May 13th, 2022|FierceBiotech|
Update: Checkmate details bleak future if $250M Regeneron merger does not closenews2022-05-13T15:16:52+00:00May 13th, 2022|FierceBiotech|
Adagio still hopes to build omicron offense for lead COVID-19 therapynews2022-05-13T13:34:38+00:00May 13th, 2022|FierceBiotech|
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS dealnews2022-05-13T12:54:12+00:00May 13th, 2022|FierceBiotech|
FDA tags Editas’ thalassemia cell therapy an orphan drug as it rounds final bend in race to clinicnews2022-05-13T11:29:35+00:00May 13th, 2022|FierceBiotech|
